The post Bearish momentum builds as price slips below key SMAs appeared on BitcoinEthereumNews.com. The Japanese Yen (JPY) remains on the front foot against theThe post Bearish momentum builds as price slips below key SMAs appeared on BitcoinEthereumNews.com. The Japanese Yen (JPY) remains on the front foot against the

Bearish momentum builds as price slips below key SMAs

The Japanese Yen (JPY) remains on the front foot against the US Dollar (USD) on Tuesday, with growing intervention risks and broad-based weakness in the Greenback reinforcing downside pressure on the pair. At the time of writing, USD/JPY trades near 153.06, hovering around over two-month lows after last week’s sharp reversal.

While there has been no official confirmation of direct intervention so far, Japanese officials have continued to issue firm warnings, saying they are watching FX developments with a strong sense of urgency and are prepared to “take appropriate action” against excessive moves.

Markets are now looking ahead to the Federal Reserve’s (Fed) interest rate decision on Wednesday. While no rate change is expected, traders will focus on the Fed Chair Jerome Powell’s tone and guidance.

Any signal that rate cuts could come later this year may weigh further on the US Dollar and push USD/JPY lower. On the other hand, a more cautious or hawkish message could offer the pair some near-term support.

From a technical perspective, the near-term outlook for USD/JPY has turned bearish, with prices slipping decisively below key moving averages. On the daily chart, the shorter-term Simple Moving Averages (SMAs) have rolled over, while the 100-day SMA still edges modestly higher. However, price is now trading below the 21, 50 and 100-day SMAs.

Momentum indicators are also leaning lower. The Moving Average Convergence Divergence (MACD) line sits below the Signal line and beneath zero, with a deepening negative histogram that suggests strengthening downside momentum.

Meanwhile, the Relative Strength Index (RSI) has fallen to around 28, pushing into oversold territory and showing the strength of the recent sell-off

On the downside, a sustained break below the 153.00 handle would expose the October 29 low at 151.54, followed by the 150.00 psychological level. A clear move below 150 would likely open the door for a deeper corrective pullback.

On the upside, a daily close back above 155.00 would help ease immediate bearish pressure. However, as long as the pair trades below the 100-day SMA, the path of least resistance remains to the downside.

Fed FAQs

Monetary policy in the US is shaped by the Federal Reserve (Fed). The Fed has two mandates: to achieve price stability and foster full employment. Its primary tool to achieve these goals is by adjusting interest rates.
When prices are rising too quickly and inflation is above the Fed’s 2% target, it raises interest rates, increasing borrowing costs throughout the economy. This results in a stronger US Dollar (USD) as it makes the US a more attractive place for international investors to park their money.
When inflation falls below 2% or the Unemployment Rate is too high, the Fed may lower interest rates to encourage borrowing, which weighs on the Greenback.

The Federal Reserve (Fed) holds eight policy meetings a year, where the Federal Open Market Committee (FOMC) assesses economic conditions and makes monetary policy decisions.
The FOMC is attended by twelve Fed officials – the seven members of the Board of Governors, the president of the Federal Reserve Bank of New York, and four of the remaining eleven regional Reserve Bank presidents, who serve one-year terms on a rotating basis.

In extreme situations, the Federal Reserve may resort to a policy named Quantitative Easing (QE). QE is the process by which the Fed substantially increases the flow of credit in a stuck financial system.
It is a non-standard policy measure used during crises or when inflation is extremely low. It was the Fed’s weapon of choice during the Great Financial Crisis in 2008. It involves the Fed printing more Dollars and using them to buy high grade bonds from financial institutions. QE usually weakens the US Dollar.

Quantitative tightening (QT) is the reverse process of QE, whereby the Federal Reserve stops buying bonds from financial institutions and does not reinvest the principal from the bonds it holds maturing, to purchase new bonds. It is usually positive for the value of the US Dollar.

Source: https://www.fxstreet.com/news/usd-jpy-price-forecast-bearish-momentum-builds-as-price-slips-below-key-smas-202601271706

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26